Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

被引:0
|
作者
Ton, Minh That [1 ]
Ho, Tri Huynh Quang [2 ]
Nguyen, Viet Lan [3 ]
Pham, Hung Manh [3 ,4 ]
Van Hoang, Sy [3 ,4 ]
Vo, Nhan Thanh [5 ,6 ]
Nguyen, Thai Quoc [3 ]
Pham, Linh Tran [3 ]
Mai, Ton Duy [4 ,7 ,8 ]
Nguyen, Thang Huy [9 ,10 ]
机构
[1] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[2] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[3] Bach Mai Hosp, Vietnam Heart Inst, Hanoi, Vietnam
[4] Hanoi Med Univ, Hanoi, Vietnam
[5] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[6] Vinmec Hosp, Cardiovasc Ctr, Ho Chi Minh City, Vietnam
[7] Bach Mai Hosp, Stroke Ctr, Hanoi, Vietnam
[8] VNU Univ Med & Pharm, Hanoi, Vietnam
[9] Peoples 115 Hosp, Cerebro Vasc Dis Dept, 527 Hanh St,Dist 10,Ward 12, Ho Chi Minh City 700000, Vietnam
[10] Pham Ngoc Thach Univ Med, Ho Chi Minh City, Vietnam
关键词
Atrial fibrillation; renal impairment; diabetes; coronary artery disease; elderly; bioprosthetic valve; DIABETES-MELLITUS; ELDERLY-PATIENTS; EMBOLISM TRIAL; RENAL-FUNCTION; ANTITHROMBOTIC THERAPY; RISK STRATIFICATION; WARFARIN; OUTCOMES; RIVAROXABAN; DABIGATRAN;
D O I
10.15420/ecr.2023.25
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Giugliano, Robert P.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 : A1 - A10
  • [22] Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation Meta-Analysis
    Wang, Kang-Ling
    Lip, Gregory Y. H.
    Lin, Shing-Jong
    Chiang, Chern-En
    STROKE, 2015, 46 (09) : 2555 - 2561
  • [23] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [24] Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study
    Ellis, Martin H.
    Dotan, Sari Greenberg
    Hammerman, Ariel
    Battat, Erez
    Derazne, Estela
    Avnery, Orly
    THROMBOSIS RESEARCH, 2018, 169 : 140 - 142
  • [25] Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
    Arnaud Bisson
    Denis Angoulvant
    Raphael Philippart
    Nicolas Clementy
    Dominique Babuty
    Laurent Fauchier
    Advances in Therapy, 2017, 34 : 1283 - 1290
  • [26] Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group
    Pharithi, Rebabonye B.
    Ranganathan, Deepti
    O'Brien, Jim
    Egom, Emmanuel E.
    Burke, Cathie
    Ryan, Daniel
    McAuliffe, Christine
    Vaughan, Marguerite
    Coughlan, Tara
    Morrissey, Edwina
    McHugh, John
    Moore, David
    Collins, Ronan
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 (01) : 101 - 108
  • [27] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [28] Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
    Cha, Myung-Jin
    Choi, Eue-Keun
    Han, Kyung-Do
    Lee, So-Ryoung
    Lim, Woo-Hyun
    Oh, Seil
    Lip, Gregory Y. H.
    STROKE, 2017, 48 (11) : 3040 - +
  • [29] Factors for recurrent stroke among Asian patients with non-valvular atrial fibrillation under non-vitamin K antagonist oral anticoagulant therapy
    Lin, Shin-Yi
    Tang, Sung-Chun
    Tsai, Li-Kai
    Yeh, Shin-Joe
    Huang, Chih-Fen
    Jeng, Jiann-Shing
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (12) : 1799 - 1806
  • [30] Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
    Khan, Ahsan A.
    Lip, Gregory Y. H.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)